Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Perrigo Company plc    PRGO   IE00BGH1M568

PERRIGO COMPANY PLC

(PRGO)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Perrigo: 2Q Earnings Snapshot

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/08/2019 | 06:47am EDT

DUBLIN (AP) _ Perrigo Co. (PRGO) on Thursday reported second-quarter earnings of $9 million.

The Dublin-based company said it had net income of 7 cents per share. Earnings, adjusted for one-time gains and costs, were 86 cents per share.

The results beat Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings of 81 cents per share.

The drug company posted revenue of $1.15 billion in the period, also beating Street forecasts. Nine analysts surveyed by Zacks expected $1.13 billion.

Perrigo expects full-year earnings in the range of $3.75 to $4.05 per share.

Perrigo shares have increased 30% since the beginning of the year, while the Standard & Poor's 500 index has climbed 15%. The stock has decreased 36% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PRGO at https://www.zacks.com/ap/PRGO

Automated Insights, source Associated Press News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PERRIGO COMPANY PLC
10/09PERRIGO : Voluntarily Halts Distribution of Ranitidine-Based Product
AQ
09/17PERRIGO : Charitable Foundation Donates More Than $20,000 to Hurricane Dorian Re..
AQ
09/06PERRIGO : Advances Consumer Self-Care Growth Strategy with Acquisition of Prevac..
AQ
09/05PERRIGO : Buys Prevacid U.S. OTC Rights From GlaxoSmithKline
DJ
08/29PERRIGO COMPANY PLC : Ex-dividend day for
FA
08/16PERRIGO : Sc 13d/a
PU
08/16PERRIGO CO PLC : Entry into a Material Definitive Agreement, Termination of a Ma..
AQ
08/08PERRIGO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
08/08PERRIGO CO PLC : Results of Operations and Financial Condition, Financial Statem..
AQ
08/08PERRIGO : 2Q Earnings Snapshot
AQ
More news
Financials (USD)
Sales 2019 4 793 M
EBIT 2019 786 M
Net income 2019 204 M
Debt 2019 2 757 M
Yield 2019 1,45%
P/E ratio 2019 41,7x
P/E ratio 2020 18,3x
EV / Sales2019 2,11x
EV / Sales2020 1,94x
Capitalization 7 337 M
Chart PERRIGO COMPANY PLC
Duration : Period :
Perrigo Company plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PERRIGO COMPANY PLC
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Average target price 54,31  $
Last Close Price 53,93  $
Spread / Highest target 11,3%
Spread / Average Target 0,70%
Spread / Lowest Target -11,0%
EPS Revisions
Managers
NameTitle
Murray S. Kessler President, Chief Executive Officer & Director
Rolf Allan Classon Chairman
Ronald Janish Executive VP-Global Operations and Supply Chain
Raymond P. Silcock Chief Financial & Accounting Officer
Thomas Farrington Chief Information Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
PERRIGO COMPANY PLC39.17%7 321
JOHNSON & JOHNSON1.29%350 587
ROCHE HOLDING AG19.25%248 542
MERCK AND COMPANY11.29%217 734
PFIZER-16.38%201 883
NOVARTIS16.20%198 243